Trial · NCT01691898
Results by group155
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 155
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 59.5 | 90% Confidence Interval 45.67 to 72.32 | percentage of participants | |
Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 61.9 | 90% Confidence Interval 41.72 to 79.43 | percentage of participants | |
Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 53.8 | 90% Confidence Interval 39.58 to 67.65 | percentage of participants | |
Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 70.0 | 90% Confidence Interval 49.22 to 86.04 | percentage of participants | |
Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Cohort C (FL): RTX + Polatuzumab | 75.0 | 90% Confidence Interval 54.44 to 89.59 | percentage of participants | |
| Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Arm A (DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 6.24 | Full Range 0.89 to 22.57 | months | |
| Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Arm A (FL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 6.47 | Full Range 0.03 to 23.52 | months | |
| Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Arm B (DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 13.37 | Full Range 0.03 to 35.68 | months | |
| Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Arm B (FL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 9.36 | Full Range 0.03 to 19.35 | months | |
| Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C) | Cohort C (FL): RTX + Polatuzumab | 12.85 | Full Range 0.03 to 22.11 | months | |
Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H | Cohort E (DLBCL): Obinutuzumab + Polatuzumab | 0 | 90% Confidence Interval 0.00 to 52.71 | percentage of participants | |
Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H | Cohort E (FL): Obinutuzumab + Polatuzumab | 50.0 | 90% Confidence Interval 2.53 to 97.47 | percentage of participants | |
Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | 35.3 | 90% Confidence Interval 21.79 to 50.82 | percentage of participants | |
Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | 0 | 90% Confidence Interval 0.00 to 10.50 | percentage of participants | |
| Number of Participants With Anti-Drug Antibodies (ADA) to Pinatuzumab Vedotin | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Baseline | 2 | participants | |
| Number of Participants With Anti-Drug Antibodies (ADA) to Pinatuzumab Vedotin | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | Post-baseline | 0 | participants | |
| Number of Participants With Anti-Drug Antibodies (ADA) to Pinatuzumab Vedotin | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Post-baseline | 0 | participants | |
| Number of Participants With ADA to Polatuzumab Vedotin | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | Baseline | 1 | participants | |
| Number of Participants With ADA to Polatuzumab Vedotin | Cohort C (FL): RTX + Polatuzumab | Baseline | 0 | participants | |
| Number of Participants With ADA to Polatuzumab Vedotin | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | Baseline | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01691898/results